Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment
of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.